{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T08:59:34Z","timestamp":1769245174990,"version":"3.49.0"},"reference-count":34,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/lfkb9461","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:01:57Z","timestamp":1762246917000},"page":"8033-8046","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and short-term prognosis of belimumab in the treatment of systemic lupus erythematosus in children"],"prefix":"10.62347","volume":"17","author":[{"given":"Yu","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta","year":"2020","unstructured":"Basta F, Fasola F, Triantafyllias K and Schwarting A. Systemic lupus erythematosus (SLE) therapy: the old and the new. Rheumatol Ther 2020; 7: 433-446.","journal-title":"Rheumatol Ther"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","article-title":"Systemic lupus erythematosus in children and young people","volume":"23","author":"Charras","year":"2021","unstructured":"Charras A, Smith E and Hedrich CM. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep 2021; 23: 20.","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.46497\/ArchRheumatol.2022.8888","article-title":"Disease characteristics in patients with juvenile- and adult-onset systemic lupus erythematosus: a multi-center comparative study","volume":"37","author":"Gamal","year":"2021","unstructured":"Gamal SM, Fouad N, Yosry N, Badr W and Sobhy N. Disease characteristics in patients with juvenile- and adult-onset systemic lupus erythematosus: a multi-center comparative study. Arch Rheumatol 2021; 37: 280-287.","journal-title":"Arch Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.55563\/clinexprheumatol\/4uc7e8","article-title":"Systemic lupus erythematosus: one year in review 2023","volume":"41","author":"Zucchi","year":"2023","unstructured":"Zucchi D, Silvagni E, Elefante E, Signorini V, Cardelli C, Trentin F, Schilirò D, Cascarano G, Valevich A, Bortoluzzi A and Tani C. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol 2023; 41: 997-1008.","journal-title":"Clin Exp Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schilirò D, Silvagni E, Ciribè B, Fattorini F, Maccarrone V, Elefante E, Signorini V, Zucchi D, Cardelli C, Bortoluzzi A and Tani C. Systemic lupus erythematosus: one year in review 2024. Clin Exp Rheumatol 2024; 42: 583-592.","DOI":"10.55563\/clinexprheumatol\/mnvmvo"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/09612033231160731","article-title":"Risk of bloodstream infection in patients with systemic lupus erythematosus exposed to prolonged medium-to-high-dose glucocorticoids","volume":"32","author":"Kim","year":"2023","unstructured":"Kim MH, Choi SR, Park JK, Lee EY, Lee EB and Park JW. Risk of bloodstream infection in patients with systemic lupus erythematosus exposed to prolonged medium-to-high-dose glucocorticoids. Lupus 2023; 32: 625-632.","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2072143","DOI":"10.1080\/21645515.2022.2072143","article-title":"Belimumab for systemic lupus erythematosus - focus on lupus nephritis","volume":"18","author":"Pl&#xFC","year":"2022","unstructured":"Plüß M, Piantoni S, Tampe B, Kim AHJ and Korsten P. Belimumab for systemic lupus erythematosus - focus on lupus nephritis. Hum Vaccin Immunother 2022; 18: 2072143.","journal-title":"Hum Vaccin Immunother"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","unstructured":"Kato H and Kahlenberg JM. Emerging biologic therapies for systemic lupus erythematosus. Curr Opin Rheumatol 2024; 36: 169-175.","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","unstructured":"Deng WP. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children. Zhongguo Dang Dai Er Ke Za Zhi 2021; 23: 1069-1074."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr and Magder LS. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86.","journal-title":"Arthritis Rheum"},{"key":"ref10","unstructured":"Chinese Rheumatology Association; National Clinical Research Center for Dermatologic and Immunologic Diseases; Chinese Systemic Lupus Erythematosus Treatment and Research Group. 2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Zhonghua Nei Ke Za Zhi 2020; 59: 172-185."},{"key":"ref11","unstructured":"Gladman DD, Ibañez D and Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Nakano M, Ota M, Takeshima Y, Iwasaki Y, Hatano H, Nagafuchi Y, Itamiya T, Maeda J, Yoshida R, Yamada S, Nishiwaki A, Takahashi H, Takahashi H, Akutsu Y, Kusuda T, Suetsugu H, Liu L, Kim K, Yin X, Bang SY, Cui Y, Lee HS, Shoda H, Zhang X, Bae SC, Terao C, Yamamoto K, Okamura T, Ishigaki K and Fujio K. Distinct transcriptome architectures underlying lupus establishment and exacerbation. Cell 2022; 185: 3375-3389, e21.","DOI":"10.1016\/j.cell.2022.07.021"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/archdischild-2017-314049","article-title":"Diagnosis and treatment of childhood-onset systemic lupus erythematosus (European evidence-based recommendations from the SHARE initiative)","volume":"104","author":"EMD","year":"2019","unstructured":"Smith EMD, Sen ES and Pain CE. Diagnosis and treatment of childhood-onset systemic lupus erythematosus (European evidence-based recommendations from the SHARE initiative). Arch Dis Child Educ Pract Ed 2019; 104: 259-264.","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1007\/s10067-019-04633-y","article-title":"Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations","volume":"38","author":"Hanaoka","year":"2019","unstructured":"Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y and Kawahata K. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations. Clin Rheumatol 2019; 38: 2785-2791.","journal-title":"Clin Rheumatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"110200","DOI":"10.1016\/j.clim.2024.110200","article-title":"New and emerging therapies for systemic lupus erythematosus","volume":"263","author":"Papachristodoulou","year":"2024","unstructured":"Papachristodoulou E and Kyttaris VC. New and emerging therapies for systemic lupus erythematosus. Clin Immunol 2024; 263: 110200.","journal-title":"Clin Immunol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Günther C and Wenzel J. Lupus erythematosus. J Dtsch Dermatol Ges 2023; 21: 426-430.","DOI":"10.1111\/ddg.15049"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","unstructured":"Gatto M, Zen M, Iaccarino L and Doria A. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 2019; 15: 30-48.","journal-title":"Nat Rev Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1208282","DOI":"10.3389\/fimmu.2023.1208282","article-title":"Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus","volume":"14","author":"Baxter","year":"2023","unstructured":"Baxter RM, Wang CS, Garcia-Perez JE, Kong DS, Coleman BM, Larchenko V, Schuyler RP, Jackson C, Ghosh T, Rudra P, Paul D, Claassen M, Rochford R, Cambier JC, Ghosh D, Cooper JC, Smith MJ and Hsieh EWY. Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus. Front Immunol 2023; 14: 1208282.","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1093\/rheumatology\/keab095","article-title":"Post-translational modifications in T cells in systemic erythematosus lupus","volume":"60","author":"Yang","year":"2021","unstructured":"Yang F, Lin J and Chen W. Post-translational modifications in T cells in systemic erythematosus lupus. Rheumatology (Oxford) 2021; 60: 2502-2516.","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","unstructured":"Kang M, Zhu J, Xu YJ, Li SN and Lai JM. Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 2022; 102: 3881-3885."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1067721","DOI":"10.3389\/fimmu.2022.1067721","article-title":"Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: a single-center, real-world, retrospective study","volume":"13","author":"Wang","year":"2022","unstructured":"Wang D, Shan C, Liu J, Zhang R, Zhu G, Gao T, Chang H, Gao S, Bai C, Nie N, Zhang Q and Lin Y. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: a single-center, real-world, retrospective study. Front Immunol 2022; 13: 1067721.","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1007\/s00431-024-05662-9","article-title":"Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis","volume":"183","author":"Li","year":"2024","unstructured":"Li H, Chen C, Yang H and Tu J. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr 2024; 183: 3987-3995.","journal-title":"Eur J Pediatr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0961203315604909","article-title":"Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab","volume":"25","author":"Roth","year":"2016","unstructured":"Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT and Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. Lupus 2016; 25: 346-54.","journal-title":"Lupus"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10067-023-06833-z","article-title":"Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review","volume":"43","author":"Elshaer","year":"2024","unstructured":"Elshaer R, Jaber S, Odeh N, Arbili L and Al-Mayouf SM. Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review. Clin Rheumatol 2024; 43: 863-877.","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","unstructured":"Blair HA and Duggan ST. Belimumab: a review in systemic lupus erythematosus. Drugs 2018; 78: 355-366.","journal-title":"Drugs"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2207671","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","unstructured":"Zhang H, Chen J, Zhang Y, Zhao N and Xu D. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis. Ren Fail 2023; 45: 2207671.","journal-title":"Ren Fail"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH and Roth DA. Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the east Asian population. Am J Kidney Dis 2023; 81: 294-306, e1.","DOI":"10.1053\/j.ajkd.2022.06.013"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial","volume":"79","author":"HI","year":"2020","unstructured":"Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D and Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 2020; 79: 1340-1348.","journal-title":"Ann Rheum Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1067721","DOI":"10.3389\/fimmu.2022.1067721","article-title":"Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: a single-center, real-world, retrospective study","volume":"13","author":"Wang","year":"2022","unstructured":"Wang D, Shan C, Liu J, Zhang R, Zhu G, Gao T, Chang H, Gao S, Bai C, Nie N, Zhang Q and Lin Y. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: a single-center, real-world, retrospective study. Front Immunol 2022; 13: 1067721.","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10067-023-06833-z","article-title":"Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review","volume":"43","author":"Elshaer","year":"2024","unstructured":"Elshaer R, Jaber S, Odeh N, Arbili L and Al-Mayouf SM. Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review. Clin Rheumatol 2024; 43: 863-877.","journal-title":"Clin Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000529675","article-title":"Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China","volume":"9","author":"Tan","year":"2023","unstructured":"Tan M, Xu J, Tan Y, Qu Z, Yu F and Zhao M. Efficacy and safety of belimumab in lupus nephritis patients: a real-world observational study in China. Kidney Dis (Basel) 2023; 9: 218-228.","journal-title":"Kidney Dis (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Zhang K, Qi T, Guo D and Liu Y. Efficacy and safety of belimumab therapy for patients with lupus nephritis: a meta-analysis and a propensity score-matched case-control study. Immun Inflamm Dis 2023; 11: e954.","DOI":"10.1002\/iid3.954"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/1744666X.2019.1564040","article-title":"Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus","volume":"15","author":"de Amorim","year":"2019","unstructured":"de Amorim JC, Frittoli RB, Pereira D, Postal M, Dertkigil SSJ, Reis F, Costallat LT and Appenzeller S. Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus. Expert Rev Clin Immunol 2019; 15: 407-416.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0167197.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T02:39:38Z","timestamp":1769135978000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/10\/ajtr0167197.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/lfkb9461","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}